GSK plc’s CRISPR Therapeutics CRSP Stock Holding History

GSK plc’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$176M	Hold	3,220,627	–	–	29.17%	1
2026 Q1	$153M	Hold	3,220,627	–	–	25.57%	1
2025 Q4	$169M	Buy	+3,220,627	New	+$193M	21.14%	2

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GSK plc's CRSP Position: Q2 2026 in Review

GSK plc held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 3,220,627 shares worth $176M. The position accounts for 29.17% of the portfolio, ranked #1.

GSK plc first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

GSK plc held 3,220,627 shares of CRISPR Therapeutics worth $176M as of Q2 2026.
GSK plc left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up 29.17% of GSK plc's portfolio in Q2 2026, its #1 holding.
GSK plc first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.